Africa–Oxford–Harvard/Hopkins Cancer Research and Clinical trials Consortium (AFROX-H2 Clinical Trials Network)

Clicks: 24
ID: 311764
2022
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #532 of 631 articles by views in science and technology of advanced materials

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 631 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
This chapter covers the AFROx-H2 Network, which includes cancer centers from different African countries with support from Oxford University and colleagues at Harvard and Johns Hopkins. A first AFROx-H2 clinical trial is in motion, with a focus on hypofractionated radiotherapy, and will be followed by trials using biomaterial drone technology developed at Harvard. This network is a great epitome of the win-win scientific initiative.
Reference Key
persistent_1771692106_6999e04a1d679 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal science and technology of advanced materials
Year 2022
DOI
10.1088/978-0-7503-3075-6ch11
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.